Brain positron emission tomography in patients with myotonic dystrophy type 1 and type 2

被引:19
作者
Peric, Stojan [1 ]
Brajkovic, Leposava [2 ]
Belanovic, Bozidar [1 ]
Ilic, Vera [1 ]
Salak-Djokic, Biljana [1 ]
Basta, Ivana [1 ]
Stojanovic, Vidosava Rakocevic [1 ]
机构
[1] Univ Belgrade, Neurol Clin, Clin Ctr Serbia, Sch Med, 6 Dr Subotica St, Belgrade 11000, Serbia
[2] Clin Ctr Serbia, Ctr Nucl Med, Belgrade, Serbia
关键词
Myotonic dystrophy type 1; Myotonic dystrophy type 2; Brain positron emission tomography; Neuropsychology; CEREBRAL-BLOOD-FLOW; COGNITIVE IMPAIRMENT; GLUCOSE-METABOLISM; PET; PARKINSONISM; MYOPATHY;
D O I
10.1016/j.jns.2017.05.013
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aim: To determine regions of reduced brain metabolism in patients with myotonic dystrophy type 1 (DM1) and type 2 (DM2) using 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET), and to analyse their potential association with cognitive deficit. Method: Study included 29 patients (16 DM1 and 13 DM2). FDG-PET and detailed neuropsychological testing were performed in both groups. Results: The most common cognitive findings were executive, visuospatial, and naming dysfunction in DM1, and executive and naming dysfunction in DM2. FDG-PET showed the most prominent glucose hypometabolism in prefrontal, temporal, and pericentral regions in both DM1 and DM2 patients, with additional affection of insula and subcortical grey matter in DM2. In DM1 patients, we found association between right frontotemporal hypometabolism and executive dysfunction (p < 0.05). In DM2 patients attention deficit was in association with prefrontal, insular, and striatal hypometabolism, as well as right frontotemporal hypometabolism (p < 0.05). Executive dysfunction in DM2 was more common in patients with prefrontal and insular hypometabolism, right parietotemporal and frontotemporal hypometabolism, as well as left striatal hypometabolism (p < 0.05). Patients with parietotemporal defect on FDG-PET were more likely to have naming dysfunction (p < 0.01). Conclusion: FDG-PET findings corresponded well with the results of neuropsychological testing. FDG-PET may be a good biomarker of central nervous system involvement in DM1 and DM2, but this hypothesis will have to be more strongly supported by larger studies. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:187 / 192
页数:6
相关论文
共 34 条
  • [21] Cognitive impairment in adult myotonic dystrophies: a longitudinal study
    Sansone, V.
    Gandossini, S.
    Cotelli, M.
    Calabria, M.
    Zanetti, O.
    Meola, G.
    [J]. NEUROLOGICAL SCIENCES, 2007, 28 (01) : 9 - 15
  • [22] Glucose metabolism and dopamine PET correlates in a patient with myotonic dystrophy type 2 and parkinsonism
    Sansone, V
    Meola, G
    Perani, D
    Fazio, F
    Garibotto, V
    Fazio, F
    Cotelli, M
    Cotelli, M
    Vitelli, E
    [J]. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2006, 77 (03) : 425 - 426
  • [23] Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness
    Schneider-Gold, Christiane
    Bellenberg, Barabara
    Prehn, Christian
    Krogias, Christos
    Schneider, Ruth
    Klein, Jan
    Gold, Ralf
    Lukas, Carsten
    [J]. PLOS ONE, 2015, 10 (06):
  • [24] Brain Connectomics' Modification to Clarify Motor and Nonmotor Features of Myotonic Dystrophy Type 1
    Serra, Laura
    Mancini, Matteo
    Silvestri, Gabriella
    Petrucci, Antonio
    Masciullo, Marcella
    Spano, Barbara
    Torso, Mario
    Mastropasqua, Chiara
    Giacanelli, Manlio
    Caltagirone, Carlo
    Cercignani, Mara
    Meola, Giovanni
    Bozzali, Marco
    [J]. NEURAL PLASTICITY, 2016, 2016
  • [25] Abnormal Functional Brain Connectivity and Personality Traits in Myotonic Dystrophy Type 1
    Serra, Laura
    Silvestri, Gabriella
    Petrucci, Antonio
    Basile, Barbara
    Masciullo, Marcella
    Makovac, Elena
    Torso, Mario
    Spano, Barbara
    Mastropasqua, Chiara
    Harrison, Neil A.
    Bianchi, Maria L. E.
    Giacanelli, Manlio
    Caltagirone, Carlo
    Cercignani, Mara
    Bozzali, Marco
    [J]. JAMA NEUROLOGY, 2014, 71 (05) : 603 - 611
  • [26] Spreen O., 1998, Administration, norms, and commentary, V2, P533
  • [27] Quality of life in patients with myotonic dystrophy type 2
    Stojanovic, Vidosava Rakocevic
    Peric, Stojan
    Paunic, Teodora
    Pesovic, Jovan
    Vujnic, Milorad
    Peric, Marina
    Nikolic, Ana
    Lavrnic, Dragana
    Pavicevic, Dusanka Savic
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2016, 365 : 158 - 161
  • [28] Myotonic dystrophy: diagnosis, management and new therapies
    Turner, Chris
    Hilton-Jones, David
    [J]. CURRENT OPINION IN NEUROLOGY, 2014, 27 (05) : 599 - 606
  • [29] EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2
    Varrone, Andrea
    Asenbaum, Susanne
    Vander Borght, Thierry
    Booij, Jan
    Nobili, Flavio
    Nagren, Kjell
    Darcourt, Jacques
    Kapucu, Oezlem L.
    Tatsch, Klaus
    Bartenstein, Peter
    Van Laere, Koen
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (12) : 2103 - 2110
  • [30] Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1
    Vielhaber, Stefan
    Jakubiczka, Sibylle
    Gaul, Charly
    Schoenfeld, Mircea Ariel
    Debska-Vielhaber, Grazyna
    Zierz, Stefan
    Heinze, Hans-Jochen
    Niessen, Heiko G.
    Kaufmann, Joern
    [J]. MUSCLE & NERVE, 2006, 34 (02) : 145 - 152